Background & Aims: Anticancer drugs are known to have great impact on spermatogenesis process and germinal epithelium. The present study is to investigate the preventive effect of Cetrorelix (GnRH antagonist) on Cyclophosphamide-induced spermatogenic defect.
Introduction
Over the last decades attempts have been made to minimize the toxic effects of chemotherapy on the ovarian tissue (1) . The alkylating drug Cyclophosphamide (CP) is a commonly used chemotherapeutic agent for cancer treatment. A number of reports described the adverse effects of Cyclophosphamide on fertility in human and animals (2) (3) (4) (5) .Chemotherapeutic agents are mostly effecting rapidly dividing cells such as cancer cells and gonadal cells.
Unfortunately, these agents cannot distinguish the difference between gonadal-from cancer-cells which leads to chemotherapeutic agents induced destruction of gonadal cells during and results in premature ovarian failure (6) (7) .Alternative methods have been developed to decrease the adverse effects of chemotherapy on ovarian functions. It is known that oogenesis is reduced by hypothalamic-pituitary axis (FSH, LH) suppression. 
Materials and Methods

Chemicals:
All chemicals and media used in the present study were purchased from Sigma-Aldrich Co. (Hamburg-Germany) unless otherwise indicated. Downloaded from ijrabms.umsu.ac.ir at 0:05 +0330 on Saturday November 2nd 2019
Animals and Ovarian Tissue Preparation:
Five to six week-old Balb/c female mice (n= 15) were housed in light and temperature controlled condition (12-h light/12-h dark, 22-24°C and 55% humidity).Food and water were freely available at all times. All the animals were handled in accordance with the guidelines of Tabriz University of Medical Sciences Committee for Animal Care.
In experimental 1 group, mice received 50 mg/kg daily Cyclophosphamide intraperitonally for five days.
In experimental 2 groups the mice in addition to Cyclophosphamide received Cetrorelix subcutaneously 0.25 mg/kg 3 times a week. Cetrorelix application started first week prior to Cyclophosphamide treatment and continued for three weeks. In all groups, mice were sacrificed by cervical dislocation 35 days after last injection and their ovaries were dissected free of fat and mesentery.
Evaluation of the Ovarian Follicular Viability:
Ovaries in control and each experimental groups (n = 5 for each group) were placed in 100 μl microdroplets 
Results
Percentages of viable ovarian follicles derived from control and experimental groups tested ovaries after trypan blue staining is presented in Table 1 . 
Discussion
We found that Cyclophosphamide treatment in mice whereby Cyclophosphamide accelerates follicular recruitment and atresia and diminishes the number of follicles in the ovaries (11, 12) .
In mice, the follicular development takes 3 to 5 weeks (13), therefore in this study a 5week treatment designed which may affect all follicular stages. Finding of present study showed significantly decreases in the number of ovarian follicles after treatment by Cyclophosphamide, these findings are in accordance with findings of Ataya et al. study (14) .
Chemotherapy is known to induce apoptosis in granulosa cells by induction of oxidative stress leading to follicular degeneration (15) , in this study, follicular degeneration in different stages of development was also observed.
Our results suggested that 35-days treatment of female mice with Cyclophosphamide can decrease ovarian folliculogenesis and steroidogenesis. Therefore, co-administration of GnRH in this experiment was maintained folliculogenesis at control.
GnRH antagonists such as Cetrorelixdirectly bind to
GnRH receptors in granulosa cells of ovarian follicles (16) . GnRH receptor expression differs among follicles in different stages (17) . Therefore, the least damage was Since ovarian tissue contains rapidly dividing cells and undergoes the most rapid mitotic activity, and also chemotherapeutic agents are known to damage primarily rapidly dividing cells, therefore, the ovarian tissue mostly is influenced by cytotoxic effects of Cyclophosphamide.
If cells are allowed to "rest period" or not-dividing activity, the oocyte survives the insult of chemotherapy and repair the lethal damage and seems to return to normal conditions (19) .It is assumed that the cells repair the damage during the resting period.
We have demonstrated that Cetrorelix can inhibit ovarian mitotic activity and cause quiescent period, leading to protect side effect of cyclophosphamid. The secretion of FSH and LH seems to be increased after radiotherapy and destructs ovarian tissue structure.
Minimizing the secretion of FSH and LH by suppression of hypothalamic-pituitary axisis used to preserve fertility during cancer therapy by reducingoogenesis and follicular proliferation (20) which is reversible after recovery of chemotherapy leading to FSH and LH secretion and improves ovarian oogenesis and fertility.
In conclusion our finding indicate that co-treatment of Cetrorelix with Cyclophosphamidcould protect different stages of ovarian follicles from adverse effect of chemotherapy.
